<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240314121035&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240314121035&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 14 Mar 2024 16:10:37 +0000</lastbuilddate>
<pubDate>Thu, 14 Mar 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Titin-Based Force Modulates Cardiac Thick and Thin Filaments</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38482667/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 14. doi: 10.1161/CIRCRESAHA.123.323988. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38482667/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38482667</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323988>10.1161/CIRCRESAHA.123.323988</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38482667</guid>
<pubDate>Thu, 14 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Anthony L Hessel</dc:creator>
<dc:creator>Michel N Kuehn</dc:creator>
<dc:creator>Nichlas M Engels</dc:creator>
<dc:creator>Devin L Nissen</dc:creator>
<dc:creator>Johanna K Freundt</dc:creator>
<dc:creator>Weikang Ma</dc:creator>
<dc:creator>Thomas C Irving</dc:creator>
<dc:creator>Wolfgang A Linke</dc:creator>
<dc:date>2024-03-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Titin-Based Force Modulates Cardiac Thick and Thin Filaments</dc:title>
<dc:identifier>pmid:38482667</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323988</dc:identifier>
</item>
<item>
<title>Modelling pre-eclampsia and its cardiovascular effects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38480793/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Mar 13. doi: 10.1038/s41569-024-01006-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38480793/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38480793</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01006-0>10.1038/s41569-024-01006-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38480793</guid>
<pubDate>Thu, 14 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Sol Olivera</dc:creator>
<dc:creator>Delyth Graham</dc:creator>
<dc:date>2024-03-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Modelling pre-eclampsia and its cardiovascular effects</dc:title>
<dc:identifier>pmid:38480793</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01006-0</dc:identifier>
</item>
<item>
<title>An epigenome editing approach induces durable silencing of Pcsk9</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38480792/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Mar 13. doi: 10.1038/s41569-024-01011-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38480792/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38480792</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01011-3>10.1038/s41569-024-01011-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38480792</guid>
<pubDate>Thu, 14 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-03-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>An epigenome editing approach induces durable silencing of Pcsk9</dc:title>
<dc:identifier>pmid:38480792</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01011-3</dc:identifier>
</item>
<item>
<title>Reply: Probing Sleep-Related Hypoxia's Impact on RV Dysfunction and PAH Survival: Uncertainties Clarified?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38479961/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 19;83(11):e109. doi: 10.1016/j.jacc.2024.01.014.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38479961/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38479961</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.014>10.1016/j.jacc.2024.01.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38479961</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Megan M Lowery</dc:creator>
<dc:creator>Nicholas S Hill</dc:creator>
<dc:creator>Lu Wang</dc:creator>
<dc:creator>Reena Mehra</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Probing Sleep-Related Hypoxia's Impact on RV Dysfunction and PAH Survival: Uncertainties Clarified?</dc:title>
<dc:identifier>pmid:38479961</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.014</dc:identifier>
</item>
<item>
<title>Probing Sleep-Related Hypoxia's Impact on RV Dysfunction and PAH Survival: Uncertainties Clarified?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38479960/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 19;83(11):e107. doi: 10.1016/j.jacc.2023.11.035.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38479960/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38479960</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.035>10.1016/j.jacc.2023.11.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38479960</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhihua Huang</dc:creator>
<dc:creator>Anqi Duan</dc:creator>
<dc:creator>Qin Luo</dc:creator>
<dc:creator>Zhihong Liu</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Probing Sleep-Related Hypoxia's Impact on RV Dysfunction and PAH Survival: Uncertainties Clarified?</dc:title>
<dc:identifier>pmid:38479960</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.035</dc:identifier>
</item>
<item>
<title>RYR2 Variant and Sudden Death in Patients With Dilated Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38479959/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 19;83(11):1105-1107. doi: 10.1016/j.jacc.2024.01.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38479959/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38479959</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.011>10.1016/j.jacc.2024.01.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38479959</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Yael Ben-Haim</dc:creator>
<dc:creator>Martin Bird</dc:creator>
<dc:creator>David Johnson</dc:creator>
<dc:creator>Saidi Mohiddin</dc:creator>
<dc:creator>Liliana Favaloro</dc:creator>
<dc:creator>Jeppe Dyrberg Andersen</dc:creator>
<dc:creator>Mary N Sheppard</dc:creator>
<dc:creator>Alan Pittman</dc:creator>
<dc:creator>Marta Futema</dc:creator>
<dc:creator>Elijah R Behr</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>RYR2 Variant and Sudden Death in Patients With Dilated Cardiomyopathy</dc:title>
<dc:identifier>pmid:38479959</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.011</dc:identifier>
</item>
<item>
<title>Restrictive Covenants and Noncompetes: An ACC Advocacy Journey</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38479958/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 19;83(11):1100-1104. doi: 10.1016/j.jacc.2024.02.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38479958/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38479958</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.002>10.1016/j.jacc.2024.02.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38479958</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:creator>Joseph E Marine</dc:creator>
<dc:creator>J Jeffrey Marshall</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Restrictive Covenants and Noncompetes: An ACC Advocacy Journey</dc:title>
<dc:identifier>pmid:38479958</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.002</dc:identifier>
</item>
<item>
<title>Histological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38479957/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>Cardiac amyloidosis is increasingly recognized as a treatable form of heart failure. Highly effective specific therapies have recently become available for the 2 most frequent forms of cardiac amyloidosis: immunoglobulin light chain amyloidosis and transthyretin (ATTR) amyloidosis. Nevertheless, initiation of specific therapies requires recognition of cardiac amyloidosis and appropriate characterization of the amyloid type. Although noninvasive diagnosis is possible for ATTR cardiac amyloidosis,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 19;83(11):1085-1099. doi: 10.1016/j.jacc.2024.01.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiac amyloidosis is increasingly recognized as a treatable form of heart failure. Highly effective specific therapies have recently become available for the 2 most frequent forms of cardiac amyloidosis: immunoglobulin light chain amyloidosis and transthyretin (ATTR) amyloidosis. Nevertheless, initiation of specific therapies requires recognition of cardiac amyloidosis and appropriate characterization of the amyloid type. Although noninvasive diagnosis is possible for ATTR cardiac amyloidosis, histological demonstration and typing of amyloid deposits is still required for a substantial number of patients with ATTR and in all patients with light chain amyloidosis and other rarer forms of cardiac amyloidosis. Amyloid histological typing can be performed using different techniques: mass spectrometry, immunohistochemistry, and immunoelectron microscopy. This review describes which patients require histological confirmation of cardiac amyloidosis along with when and how to type amyloid deposits in histologic specimens. Furthermore, it covers the characteristics and limitations of the different typing methods that are available in clinical practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38479957/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38479957</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.010>10.1016/j.jacc.2024.01.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38479957</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Esther Gonzalez-Lopez</dc:creator>
<dc:creator>Ellen D McPhail</dc:creator>
<dc:creator>Clara Salas-Anton</dc:creator>
<dc:creator>Fernando Dominguez</dc:creator>
<dc:creator>Morie A Gertz</dc:creator>
<dc:creator>Angela Dispenzieri</dc:creator>
<dc:creator>Surendra Dasari</dc:creator>
<dc:creator>Paolo Milani</dc:creator>
<dc:creator>Laura Verga</dc:creator>
<dc:creator>Martha Grogan</dc:creator>
<dc:creator>Giovanni Palladini</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Histological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:38479957</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.010</dc:identifier>
</item>
<item>
<title>Rehospitalization After PCI vs CABG for Left Main Disease: Refocusing Our Lens</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38479956/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 19;83(11):1082-1084. doi: 10.1016/j.jacc.2024.01.028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38479956/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38479956</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.028>10.1016/j.jacc.2024.01.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38479956</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Wayne B Batchelor</dc:creator>
<dc:creator>Abdulla A Damluji</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Rehospitalization After PCI vs CABG for Left Main Disease: Refocusing Our Lens</dc:title>
<dc:identifier>pmid:38479956</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.028</dc:identifier>
</item>
<item>
<title>Incidence, Predictors, and Impact of Hospital Readmission After Revascularization for Left Main Coronary Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38479955/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the EXCEL trial, readmissions during 5-year follow-up after revascularization for LMCAD were common and more frequent after PCI than CABG. Readmissions were associated with an increased risk of all-cause death, more so after PCI than with CABG.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 19;83(11):1073-1081. doi: 10.1016/j.jacc.2024.01.012.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The frequency of and relationship between hospital readmissions and outcomes after revascularization for left main coronary artery disease (LMCAD) are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to study the incidence, predictors, and clinical impact of readmissions following percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for LMCAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the EXCEL (XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial, 1,905 patients with LMCAD were randomized to PCI vs CABG. The cumulative incidence of readmissions was analyzed with multivariable Anderson-Gill and joint frailty models to account for recurrent events and the competing risk of death. The impact of readmission on subsequent mortality within 5-year follow-up was determined in a time-adjusted Cox proportional hazards model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Within 5 years, 1,868 readmissions occurred in 851 of 1,882 (45.2%) hospital survivors (2.2 ± 1.9 per patient with readmission[s], range 1-16), approximately one-half for cardiovascular causes and one-half for noncardiovascular causes (927 [49.6%] and 941 [50.4%], respectively). One or more readmissions occurred in 463 of 942 (48.6%) PCI patients vs 388 of 940 (41.8%) CABG patients (P = 0.003). After multivariable adjustment, PCI remained an independent predictor of readmission (adjusted HR: 1.22; 95% CI: 1.10-1.35; P &lt; 0.0001), along with female sex, comorbidities, and the extent of CAD. Readmission was independently associated with subsequent all-cause death, with interaction testing indicating a higher risk after PCI than CABG (adjusted HR: 5.72; 95% CI: 3.42-9.55 vs adjusted HR: 2.72; 95% CI: 1.64-4.88, respectively; P<sub>int</sub> = 0.03).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the EXCEL trial, readmissions during 5-year follow-up after revascularization for LMCAD were common and more frequent after PCI than CABG. Readmissions were associated with an increased risk of all-cause death, more so after PCI than with CABG.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38479955/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38479955</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.012>10.1016/j.jacc.2024.01.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38479955</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Ioanna Kosmidou</dc:creator>
<dc:creator>Bahira Shahim</dc:creator>
<dc:creator>Ovidiu Dressler</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Marie-Claude Morice</dc:creator>
<dc:creator>John D Puskas</dc:creator>
<dc:creator>David E Kandzari</dc:creator>
<dc:creator>Dimitri Karmpaliotis</dc:creator>
<dc:creator>W Morris Brown</dc:creator>
<dc:creator>Nicholas J Lembo</dc:creator>
<dc:creator>Adrian P Banning</dc:creator>
<dc:creator>Arie Pieter Kappetein</dc:creator>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>Joseph F Sabik</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Incidence, Predictors, and Impact of Hospital Readmission After Revascularization for Left Main Coronary Disease</dc:title>
<dc:identifier>pmid:38479955</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.012</dc:identifier>
</item>
<item>
<title>Reducing Contrast Volume to Protect the Kidneys: As Low as Reasonably Achievable</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38479954/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 19;83(11):1070-1072. doi: 10.1016/j.jacc.2024.01.018.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38479954/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38479954</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.018>10.1016/j.jacc.2024.01.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38479954</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Hitinder S Gurm</dc:creator>
<dc:creator>Michael R Rudnick</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reducing Contrast Volume to Protect the Kidneys: As Low as Reasonably Achievable</dc:title>
<dc:identifier>pmid:38479954</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.018</dc:identifier>
</item>
<item>
<title>Kidney Injury After Minimal Radiographic Contrast Administration in Patients With Acute Coronary Syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38479953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CM volume reduction obtained using the CM diversion system is effective for prevention of AKI in patients with ACS undergoing invasive procedures. (REnal Insufficiency Following Contrast MEDIA Administration TriaL IV [REMEDIALIV]: NCT04714736).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 19;83(11):1059-1069. doi: 10.1016/j.jacc.2024.01.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Acute kidney injury (AKI) is common in patients with acute coronary syndromes (ACS) treated by percutaneous coronary intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: Contrast media (CM) volume minimization has been advocated for prevention of AKI. The DyeVert CM diversion system (Osprey Medical, Inc) is designed to reduce CM volume during coronary procedures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this randomized, single-blind, investigator-driven clinical trial conducted in 4 Italian centers from February 4, 2020 to September 13, 2022, 550 participants with ACS were randomly assigned in a 1:1 ratio to the following: 1) the contrast volume reduction (CVR) group (n = 276), in which CM injection was handled by the CM diversion system; and 2) the control group (n = 274), in which a conventional manual or automatic injection syringe was used. The primary endpoint was the rate of AKI, defined as a serum creatinine (sCr) increase ≥0.3 mg/dL within 48 hours after CM exposure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: There were 412 of 550 (74.5%) participants with ST-segment elevation myocardial infarction (211 of 276 [76.4%] in the CVR group and 201 of 274 [73.3%] in the control group). The CM volume was lower in the CVR group (95 ± 30 mL vs 160 ± 23 mL; P &lt; 0.001). Seven participants (1 in the CVR group and 6 in the control group) did not have postprocedural sCr values. AKI occurred in 44 of 275 (16%) participants in the CVR group and in 65 of 268 (24.3%) participants in the control group (relative risk: 0.66; 95% CI: 0.47-0.93; P = 0.018).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CM volume reduction obtained using the CM diversion system is effective for prevention of AKI in patients with ACS undergoing invasive procedures. (REnal Insufficiency Following Contrast MEDIA Administration TriaL IV [REMEDIALIV]: NCT04714736).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38479953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38479953</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.016>10.1016/j.jacc.2024.01.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38479953</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Carlo Briguori</dc:creator>
<dc:creator>Cristina Quintavalle</dc:creator>
<dc:creator>Enrica Mariano</dc:creator>
<dc:creator>Alessandro D'Agostino</dc:creator>
<dc:creator>Mario Scarpelli</dc:creator>
<dc:creator>Amelia Focaccio</dc:creator>
<dc:creator>Giuseppe Biondi Zoccai</dc:creator>
<dc:creator>Salvatore Evola</dc:creator>
<dc:creator>Giovanni Esposito</dc:creator>
<dc:creator>Giuseppe Massimo Sangiorgi</dc:creator>
<dc:creator>Gerolama Condorelli</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Kidney Injury After Minimal Radiographic Contrast Administration in Patients With Acute Coronary Syndromes</dc:title>
<dc:identifier>pmid:38479953</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.016</dc:identifier>
</item>
<item>
<title>Atrial Fibrillation Management With Antiarrhythmic Drug Therapy: Balancing Benefits and Bradycardia Risks</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38479952/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 19;83(11):1039-1041. doi: 10.1016/j.jacc.2024.01.015.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38479952/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38479952</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.015>10.1016/j.jacc.2024.01.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38479952</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Sanjay Dixit</dc:creator>
<dc:creator>Justice U Oranefo</dc:creator>
<dc:creator>Mohamad Raad</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Atrial Fibrillation Management With Antiarrhythmic Drug Therapy: Balancing Benefits and Bradycardia Risks</dc:title>
<dc:identifier>pmid:38479952</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.015</dc:identifier>
</item>
<item>
<title>Association of Antiarrhythmic Drug Therapy With Syncope and Pacemaker Implantation in Patients With Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38479951/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study showed an association between AADs and risk of pacemaker implantation or syncope, a consistent finding across various subgroups. Precise evaluation of such risk should be undertaken before prescription of AADs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 19;83(11):1027-1038. doi: 10.1016/j.jacc.2024.01.013.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Early rhythm control therapy mainly with antiarrhythmic drugs (AADs) for new-onset atrial fibrillation (AF) reduces major adverse cardiovascular events. However, negative dromotropic effects of AADs via ion channel blocking may cause bradyarrhythmias.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to evaluate the association between AAD use and the risk of pacemaker implantation or syncope in patients with new-onset AF receiving early rhythm control therapy with AADs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study was based on data from the Korean National Health Insurance Service system. We screened all new-onset AF diagnoses that occurred from 2013 to 2019 and identified patients who were prescribed AADs within 1 year of AF diagnosis. The risk of pacemaker implantation or syncope was compared between AAD users and nonusers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 770,977 new-onset AF cases were identified and 142,141 patients were prescribed AADs. After multivariate adjustment, use of AADs was associated with 3.5-, 2.0-, and 5.0-fold increased risk of pacemaker implantation or syncope, syncope, and pacemaker implantation, respectively. Propensity score-matched analysis revealed similar results, demonstrating a significant association between AAD use and the risk of pacemaker implantation or syncope. This association was consistent across various subgroups. Women were more susceptible to adverse effects of AADs than men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study showed an association between AADs and risk of pacemaker implantation or syncope, a consistent finding across various subgroups. Precise evaluation of such risk should be undertaken before prescription of AADs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38479951/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38479951</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.013>10.1016/j.jacc.2024.01.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38479951</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Yun Gi Kim</dc:creator>
<dc:creator>Hyoung Seok Lee</dc:creator>
<dc:creator>Hoseob Kim</dc:creator>
<dc:creator>Mina Kim</dc:creator>
<dc:creator>Joo Hee Jeong</dc:creator>
<dc:creator>Yun Young Choi</dc:creator>
<dc:creator>Jaemin Shim</dc:creator>
<dc:creator>Jong-Il Choi</dc:creator>
<dc:creator>Young-Hoon Kim</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Antiarrhythmic Drug Therapy With Syncope and Pacemaker Implantation in Patients With Atrial Fibrillation</dc:title>
<dc:identifier>pmid:38479951</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.013</dc:identifier>
</item>
<item>
<title>The art of deciphering and communicating cardiovascular risk: getting it right</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38478708/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 13:ehae103. doi: 10.1093/eurheartj/ehae103. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38478708/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38478708</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae103>10.1093/eurheartj/ehae103</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38478708</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Safi U Khan</dc:creator>
<dc:creator>Sadeer A-Kindi</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The art of deciphering and communicating cardiovascular risk: getting it right</dc:title>
<dc:identifier>pmid:38478708</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae103</dc:identifier>
</item>
<item>
<title>What's VAT All About-The Clue Is in the Genetics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477927/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 13. doi: 10.1001/jamacardio.2024.0092. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477927/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38477927</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0092>10.1001/jamacardio.2024.0092</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477927</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Sharlene M Day</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>What's VAT All About-The Clue Is in the Genetics</dc:title>
<dc:identifier>pmid:38477927</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0092</dc:identifier>
</item>
<item>
<title>Quantitative Coronary Angiography vs Intravascular Ultrasonography to Guide Drug-Eluting Stent Implantation: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477913/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Findings of this randomized clinical trial indicate that QCA and IVUS guidance during PCI showed similar rates of target lesion failure at 12 months. However, due to the lower-than-expected rates of target lesion failure in this trial, the findings should be interpreted with caution.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 13. doi: 10.1001/jamacardio.2024.0059. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Although intravascular ultrasonography (IVUS) guidance promotes favorable outcomes after percutaneous coronary intervention (PCI), many catheterization laboratories worldwide lack access.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate whether systematic implementation of quantitative coronary angiography (QCA) to assist angiography-guided PCI could be an alternative strategy to IVUS guidance during stent implantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, noninferiority clinical trial enrolled adults (aged ≥18 years) with chronic or acute coronary syndrome and angiographically confirmed native coronary artery stenosis requiring PCI. Patients were enrolled in 6 cardiac centers in Korea from February 23, 2017, to August 23, 2021, and follow-up occurred through August 25, 2022. All principal analyses were performed according to the intention-to-treat principle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: After successful guidewire crossing of the first target lesion, patients were randomized in a 1:1 ratio to receive either QCA- or IVUS-guided PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was target lesion failure at 12 months, defined as a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. The trial was designed assuming an event rate of 8%, with the upper limit of the 1-sided 97.5% CI of the absolute difference in 12-month target lesion failure (QCA-guided PCI minus IVUS-guided PCI) to be less than 3.5 percentage points for noninferiority.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The trial included 1528 patients who underwent PCI with QCA guidance (763; mean [SD] age, 64.1 [9.9] years; 574 males [75.2%]) or IVUS guidance (765; mean [SD] age, 64.6 [9.5] years; 622 males [81.3%]). The post-PCI mean (SD) minimum lumen diameter was similar between the QCA- and IVUS-guided PCI groups (2.57 [0.55] vs 2.60 [0.58] mm, P = .26). Target lesion failure at 12 months occurred in 29 of 763 patients (3.81%) in the QCA-guided PCI group and 29 of 765 patients (3.80%) in the IVUS-guided PCI group (absolute risk difference, 0.01 percentage points [95% CI, -1.91 to 1.93 percentage points]; hazard ratio, 1.00 [95% CI, 0.60-1.68]; P = .99). There was no difference in the rates of stent edge dissection (1.2% vs 0.7%, P = .25), coronary perforation (0.2% vs 0.4%, P = .41), or stent thrombosis (0.53% vs 0.66%, P = .74) between the QCA- and IVUS-guided PCI groups. The risk of the primary end point was consistent regardless of subgroup, with no significant interaction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Findings of this randomized clinical trial indicate that QCA and IVUS guidance during PCI showed similar rates of target lesion failure at 12 months. However, due to the lower-than-expected rates of target lesion failure in this trial, the findings should be interpreted with caution.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02978456.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477913/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38477913</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0059>10.1001/jamacardio.2024.0059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477913</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Pil Hyung Lee</dc:creator>
<dc:creator>Soon Jun Hong</dc:creator>
<dc:creator>Hyun-Sook Kim</dc:creator>
<dc:creator>Young Won Yoon</dc:creator>
<dc:creator>Jong-Young Lee</dc:creator>
<dc:creator>Seung-Jin Oh</dc:creator>
<dc:creator>Ji Sung Lee</dc:creator>
<dc:creator>Soo-Jin Kang</dc:creator>
<dc:creator>Young-Hak Kim</dc:creator>
<dc:creator>Seong-Wook Park</dc:creator>
<dc:creator>Seung-Whan Lee</dc:creator>
<dc:creator>Cheol Whan Lee</dc:creator>
<dc:creator>GUIDE-DES Trial Research Group</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Quantitative Coronary Angiography vs Intravascular Ultrasonography to Guide Drug-Eluting Stent Implantation: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38477913</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0059</dc:identifier>
</item>
<item>
<title>Moving Beyond Conventional Guesstimation to Guide PCI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477911/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 13. doi: 10.1001/jamacardio.2024.0071. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477911/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38477911</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0071>10.1001/jamacardio.2024.0071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477911</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Moving Beyond Conventional Guesstimation to Guide PCI</dc:title>
<dc:identifier>pmid:38477911</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0071</dc:identifier>
</item>
<item>
<title>Cardiovascular Significance and Genetics of Epicardial and Pericardial Adiposity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that epicardial and pericardial adiposity was associated with incident cardiovascular diseases, but this may largely reflect a metabolically unhealthy adiposity phenotype similar to abdominal visceral adiposity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 13. doi: 10.1001/jamacardio.2024.0080. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Epicardial and pericardial adipose tissue (EPAT) has been associated with cardiovascular diseases such as atrial fibrillation or flutter (AF) and coronary artery disease (CAD), but studies have been limited in sample size or drawn from selected populations. It has been suggested that the association between EPAT and cardiovascular disease could be mediated by local or paracrine effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the association of EPAT with prevalent and incident cardiovascular disease and to elucidate the genetic basis of EPAT in a large population cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: A deep learning model was trained to quantify EPAT area from 4-chamber magnetic resonance images using semantic segmentation. Cross-sectional and prospective cardiovascular disease associations were evaluated, controlling for sex and age. Prospective associations were additionally controlled for abdominal visceral adipose tissue (VAT) volumes. A genome-wide association study was performed, and a polygenic score (PGS) for EPAT was examined in independent FinnGen cohort study participants. Data analyses were conducted from March 2022 to December 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: The primary exposures were magnetic resonance imaging-derived continuous measurements of epicardial and pericardial adipose tissue area and visceral adipose tissue volume.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Prevalent and incident CAD, AF, heart failure (HF), stroke, and type 2 diabetes (T2D).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: After exclusions, this study included 44 475 participants (mean [SD] age, 64.1 [7.7] years; 22 972 female [51.7%]) from the UK Biobank. Cross-sectional and prospective cardiovascular disease associations were evaluated for a mean (SD) of 3.2 (1.5) years of follow-up. Prospective associations were additionally controlled for abdominal VAT volumes for 38 527 participants. A PGS for EPAT was examined in 453 733 independent FinnGen cohort study participants. EPAT was positively associated with male sex (β = +0.78 SD in EPAT; P &lt; 3 × 10-324), age (Pearson r = 0.15; P = 9.3 × 10-229), body mass index (Pearson r = 0.47; P &lt; 3 × 10-324), and VAT (Pearson r = 0.72; P &lt; 3 × 10-324). EPAT was more elevated in prevalent HF (β = +0.46 SD units) and T2D (β = +0.56) than in CAD (β = +0.23) or AF (β = +0.18). EPAT was associated with incident HF (hazard ratio [HR], 1.29 per +1 SD in EPAT; 95% CI, 1.17-1.43), T2D (HR, 1.63; 95% CI, 1.51-1.76), and CAD (HR, 1.19; 95% CI, 1.11-1.28). However, the associations were no longer significant when controlling for VAT. Seven genetic loci were identified for EPAT, implicating transcriptional regulators of adipocyte morphology and brown adipogenesis (EBF1, EBF2, and CEBPA) and regulators of visceral adiposity (WARS2 and TRIB2). The EPAT PGS was associated with T2D (odds ratio [OR], 1.06; 95% CI, 1.05-1.07; P =3.6 × 10-44), HF (OR, 1.05; 95% CI, 1.04-1.06; P =4.8 × 10-15), CAD (OR, 1.04; 95% CI, 1.03-1.05; P =1.4 × 10-17), AF (OR, 1.04; 95% CI, 1.03-1.06; P =7.6 × 10-12), and stroke in FinnGen (OR, 1.02; 95% CI, 1.01-1.03; P =3.5 × 10-3) per 1 SD in PGS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that epicardial and pericardial adiposity was associated with incident cardiovascular diseases, but this may largely reflect a metabolically unhealthy adiposity phenotype similar to abdominal visceral adiposity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38477908</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0080>10.1001/jamacardio.2024.0080</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477908</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Joel T Rämö</dc:creator>
<dc:creator>Shinwan Kany</dc:creator>
<dc:creator>Cody R Hou</dc:creator>
<dc:creator>Samuel F Friedman</dc:creator>
<dc:creator>Carolina Roselli</dc:creator>
<dc:creator>Victor Nauffal</dc:creator>
<dc:creator>Satoshi Koyama</dc:creator>
<dc:creator>Juha Karjalainen</dc:creator>
<dc:creator>Mahnaz Maddah</dc:creator>
<dc:creator>Aarno Palotie</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>James P Pirruccello</dc:creator>
<dc:creator>FinnGen</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardiovascular Significance and Genetics of Epicardial and Pericardial Adiposity</dc:title>
<dc:identifier>pmid:38477908</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0080</dc:identifier>
</item>
<item>
<title>A Female in Her 50s With Caseating Mitral Annulus Calcification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 13. doi: 10.1001/jamacardio.2024.0074. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38477890</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0074>10.1001/jamacardio.2024.0074</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477890</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Iva Minga</dc:creator>
<dc:creator>Vinesh Appadurai</dc:creator>
<dc:creator>Vera Rigolin</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>A Female in Her 50s With Caseating Mitral Annulus Calcification</dc:title>
<dc:identifier>pmid:38477890</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0074</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240314121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 1;9(3):202. doi: 10.1001/jamacardio.2023.3651.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240314121035&v=2.18.0.post9+e462414">38477842</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3651>10.1001/jamacardio.2023.3651</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477842</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:38477842</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3651</dc:identifier>
</item>





























</channel>
</rss>